Core Insights - Silexion Therapeutics Corp. has released promising preclinical data for its drug SIL204, which shows effective targeting and anti-tumor activity against pancreatic cancer metastasis [1][3][4] Group 1: Study Findings - SIL204 demonstrated successful biodistribution to all major metastatic sites after a single subcutaneous injection at a dose of 5 mg/mouse, which is a mid-range human equivalent dose for planned clinical trials [2][3] - Significant reductions in tumor burden were observed at day 7 across evaluated organs, with statistically significant reductions (p<0.01) noted in the peritoneum, lung, and intestine [3] - The liver, a common site for pancreatic cancer metastasis, also showed measurable tumor burden reduction, validating the drug's potential for clinical application [4] Group 2: Future Plans - The company is expanding tissue culture studies across various cancer types and KRAS mutations to further explore SIL204's pan-KRAS potential, with results anticipated soon [5] - Silexion is on track to initiate Phase 2/3 clinical trials for its dual-route administration approach in the first half of 2026, with regulatory submissions planned for late 2025 and early 2026 [5] Group 3: Financial Actions - Silexion Therapeutics has priced a public offering of 1.5 million shares along with series A and B warrants, each at $4 per share, which will also have an exercise price of $4.00 per share [6] - Following the news, SLXN stock increased by 14.83%, reaching $5.15 [6]
Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data